A $46M Bet on a New Way to Treat the Most Common Inherited Kidney Disease

Jan de Vries · 2026-08-07

When a biotech company lands a massive funding round, it's easy to get lost in the dollar signs. But the real story is often about the patients waiting for better options. That's exactly what's happening with Mironid, a Glasgow-based biopharmaceutical firm that just closed a $46 million Series B round to push its lead drug candidate through clinical development. The money is earmarked for a treatment targeting Autosomal Dominant Polycystic Kidney Disease, or ADPKD. If you haven't heard of it, you're not alone. But it's the most common hereditary kidney disorder on the planet, affecting more than 12 million people worldwide. And for half of those patients, kidney failure becomes a reality by age 60. That's a sobering statistic. ### Who's backing this ambitious bet? The round was led by the Scottish National Investment Bank, but it wasn't a solo act. A syndicate of existing backers joined in, including Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. When you see that kind of lineup, it's a signal that the science is being taken seriously by people who know what they're looking at. Neil Wilkie, Mironid's CEO, didn't mince words about what this means for the company. He called the financing a "strong validator" of their approach. And honestly, it's hard to argue with that. When sophisticated investors double down on your vision, it carries weight. ### The science behind the headlines Here's where things get interesting. Mironid wasn't born yesterday. The company spun out of the University of Strathclyde and Heriot-Watt University back in 2015, building on over three decades of research into PDE biology by Professor Miles Houslay. That's a deep scientific foundation, not a flash-in-the-pan idea. Their lead candidate is what they call a LoAc small molecule. Without getting too deep into the weeds, it's designed to directly target cyclic AMP, or cAMP, a cellular signal that's active at every stage of ADPKD. This signal drives both cell proliferation and fluid secretion within the cysts that wreak havoc on kidneys. Here's the clever part: by modulating cAMP, Mironid believes it can prevent new cyst formation while arresting the growth of existing ones. Preclinical data has shown significant efficacy and a favorable safety profile, including reductions in both cyst number and kidney volume. If that translates to humans, it could offer a more durable treatment option with a better side-effect profile than what's currently available. ### Why this matters beyond the checkbook ADPKD is caused predominantly by mutations in the PKD1 or PKD2 genes, leading to uncontrolled growth of fluid-filled cysts. Eventually, many patients face kidney failure. The current treatment landscape has limitations, which is why a fresh approach like this is so important. Mironid's pipeline doesn't stop at ADPKD either. They're also targeting phosphodiesterase 4 (PDE4) enzymes, which play a key role in cell signaling pathways linked to disease progression. And they're exploring applications in major inflammatory diseases and cancer. This isn't a one-trick pony. Paul Callaghan, Investment Director at the Scottish National Investment Bank, summed it up nicely: "Mironid exemplifies Scotland's growing reputation for biotech innovation." He's right. This is world-class research being translated into clinical progress, and potentially, real patient benefit. ### What's next for Mironid? The fresh capital follows an earlier Series A extension, bringing the company's total funding since inception to roughly $47 million. That's a solid war chest for a company at this stage. Going forward, the focus is on advancing the clinical development of their lead candidate. The goal is straightforward: bring a new treatment option to patients who desperately need one. It won't be easy, and clinical trials are notoriously unpredictable. But with this kind of backing and a scientifically sound approach, Mironid has put itself in a position to make a real difference. For anyone watching the biotech space, this is one to keep an eye on. The science is promising, the team is experienced, and the funding is now in place. The next few years will tell us whether this approach lives up to its potential. But for the millions of people living with ADPKD, there's reason to be hopeful.